Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of April 30, 2025 • 10:41 AM ET

Date/Time Source News Release
04/30/2025 07:25 AM EDT PR Newswire Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation
04/29/2025 04:08 PM EDT Newsfile ROSEN, A LONGSTANDING FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATNM
04/29/2025 01:09 PM EDT GlobeNewswire Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM
04/29/2025 10:50 AM EDT GlobeNewswire ATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
04/28/2025 09:00 PM EDT GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and Cerevel and Encourages Investors to Contact the Firm
04/28/2025 06:28 PM EDT PR Newswire ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit
04/28/2025 02:19 PM EDT GlobeNewswire ROSEN, A LEADING NATIONAL FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATNM
04/28/2025 12:27 PM EDT GlobeNewswire The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM
04/28/2025 08:30 AM EDT PR Newswire Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting
04/28/2025 05:45 AM EDT PR Newswire May 27, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ATNM
Page

Additional News

As of April 30, 2025 • 10:41 AM ET

Date/Time Source News Release
04/29/2025 04:45 PM EDT ACCESS Newswire IA Levi & Korsinsky Notifies Shareholders of Actinium Pharmaceuticals, Inc. (ATNM) of a Class Action Lawsuit and an Upcoming Deadline
04/29/2025 04:00 PM EDT ACCESS Newswire IA Actinium Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Actinium Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 27, 2025 - ATNM
04/29/2025 03:42 PM EDT ACCESS Newswire IA ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATNM
04/29/2025 11:15 AM EDT ACCESS Newswire IA Contact Levi & Korsinsky by May 27, 2025 Deadline to Join Class Action Against Actinium Pharmaceuticals, Inc. (ATNM)
04/29/2025 10:45 AM EDT ACCESS Newswire IA Shareholders That Lost Money on Actinium Pharmaceuticals, Inc. (ATNM) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
04/29/2025 07:15 AM EDT ACCESS Newswire IA Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ATNM
04/28/2025 07:00 PM EDT ACCESS Newswire IA Investors in Actinium Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNM
04/28/2025 04:45 PM EDT ACCESS Newswire IA May 27, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ATNM
04/28/2025 02:45 PM EDT ACCESS Newswire IA Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
04/28/2025 10:15 AM EDT ACCESS Newswire IA Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNM
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.